Nektar Therapeutics kicked off the trading day on 10/10/19 with a price decrease of -3.47%, equivalent to -$0.58 relative change for the day. Taking a more long-term approach, NKTR had a 52-week range of $16.10 to $52.70. At the time of this article’s publishing, this stock is trading at $16.13 after starting the trading session at $16.70. At the time of writing, this stock’s 50-day Moving Average stands at $19.69, while the 200-day Moving Average of this stock is currently $31.77.
Currently, this company’s share volume is sitting at $2777234, but has maintained average daily volume of $3.67M. This stock has generated an average Year to Date volume of $2.35 million, alongside an average 20-day volume of $5.06 million. This publicly-traded company’s shares outstanding now amounts to $174.55 million, simultaneously with a float of $173.73 million. The organization now has a market capitalization sitting at $2.82 billion.
Nektar Therapeutics(NKTR) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Nektar Therapeutics’s current insider ownership accounts for 1.10%, in contrast to 97.00% institutional ownership. According to the most recent latest insider trade that took place on Sep 30 this organization’s Director sold 2,375 at the rate of 18.06, making the entire transaction hit 42,893 in total value, affecting insider ownership by 22,375. Preceding that transaction, on Sep 27 Company’s Director sold 3,000 at a price of 17.84, making the whole transaction’s value amount to 53,520. This particular insider is now the holder of 26,700 in total.
If we take a glance at the Ownership summary of Nektar Therapeutics’s stock, Institutional holders make up 97.00% of its total stock ownership. All together, they are the legal holders of 174.55M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Invesco Advisers, Inc. owns 21,635,280 shares, with PRIMECAP Management Co. in 2nd place owning 19,090,422 shares and Fidelity Management & Research Co. in third place with total ownership of 18,372,971 shares.
Nektar Therapeutics (NKTR) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.63 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.8) by $0.17.
This company achieved a net margin of -354.9 while generating a return on equity of -24.7. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
Nektar Therapeutics’s EPS increase for this current 12-month fiscal period is 289.50%, and is forecasted to reach -2.51 in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will decrease by -7.30% through the next 5 years, which can be compared against the 36.30% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Nektar Therapeutics, this organization’s Quick Ratio in the last reported quarter now stands at 14.00. The company has managed to achieve an average true range (ATR) of 1.08. Alongside those, its Beta score is 2.60.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 23.64 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 1.81, whereas its price to cash per share for the last quarter landed at 8.68.
In the same vein, NKTR’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -2.43, a figure that is expected to reach -0.74 in the next reported quarter, and analysts expect it will be -2.51 at the market close of one year from today’s date.